Inclusion Criteria:

- Confirmation of non-myeloid cancer (myeloproliferative disorders will be excluded).

- Hemoglobin concentration ≤ 11.0 g/dL.

- Age ≥ 18 years.

- Karnofsky performance status ≥ 60%.

- Anemia predominantly due to cancer or chemotherapy.

- Serum creatinine concentration ≤ 2.0 mg/dL.

- Total serum bilirubin ≤ 1.5 times the upper limit of normal.

- Nutritional status adequate to provide vitamin B12 and folate within the normal
limits.

- Capacity to complete the web-based functional status, symptom and quality of life
assessments.

- Ability to give informed consent.

Exclusion Criteria:

- Untreated symptomatic primary or metastatic cancer involving the central nervous
system.

- History of clinically significant iron deficiency.

- Greater than two red blood cell transfusions within 2 weeks of registration or any
red blood cell transfusion within 7 days of registration.

- Received epoetin alfa or darbepoetin alfa therapy within 3 weeks prior to
randomization.

- History of a seizure disorder.

- Unstable angina, congestive heart failure (New York Heart Association > class II or
known ejection fraction < 40%) or uncontrolled cardiac arrhythmias.

- Uncontrolled hypertension defined as a diastolic blood pressure > 100 mmHg.

- Clinical evidence of active infection or inflammatory diseases such as rheumatoid
arthritis. Subjects with active rheumatoid arthritis are excluded.

- Known positive test for human immunodeficiency virus infection.

- Known primary hematological disorder which could cause anemia such as sickle cell
anemia.

- Pregnant or breast-feeding.

- Not using adequate contraception if of childbearing potential.

- Known hypersensitivity to any recombinant mammalian-derived product.